arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

Kyverna Therapeutics, Inc.

KYTX

$7.96 ▲ +0.20 (+2.58%) at close

14 Visible periods

19 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Kyverna Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $481.1M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -16.7% ↘

FCF / Share $-0.69

Trailing P/E —

Price / Book 2.5x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

14-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-39.73M

↑ +11.0% —

FCF / Share Free cash flow per share

$-0.69

↑ +33.8% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Financial Health ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
EPS Growth YoY (%)	35.9% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	10.2% Fair ↑ Fair Improving Year-over-year change in earnings per share Optimal: > 10%	-6.2% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-44.8% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	8.0% Fair ↓ Fair Declining Year-over-year change in earnings per share Optimal: > 10%	96.7% Excellent → Excellent Stable Year-over-year change in earnings per share Optimal: > 10%	96.6% Excellent → Excellent Stable Year-over-year change in earnings per share Optimal: > 10%	96.8% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	90.7% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—
Net Income Growth YoY (%)	11.0% Fair ↑ Fair Improving Year-over-year change in net income	-0.8% Weak ↑ Weak Improving Year-over-year change in net income	-67.2% Weak ↑ Weak Improving Year-over-year change in net income	-67.2% Weak ↑ Weak Improving Year-over-year change in net income	-67.2% Weak ↑ Weak Improving Year-over-year change in net income	-81.4% Weak ↑ Weak Improving Year-over-year change in net income	-139.5% Weak → Weak Stable Year-over-year change in net income	-139.5% Weak Weak Year-over-year change in net income	-139.5% Weak Weak Year-over-year change in net income	—	—	—	—	—
FCF Growth YoY (%)	33.8% Excellent Excellent Year-over-year change in free cash flow	—	-56.1% Weak Weak Year-over-year change in free cash flow	—	5.3% Fair Fair Year-over-year change in free cash flow	—	96.3% Excellent Excellent Year-over-year change in free cash flow	—	91.2% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
FCF / Net Income (x)	1.05x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.97x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.72x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.01x Fair → Fair Stable Free cash flow relative to reported net income Optimal: > 1x	1.00x Fair → Fair Stable Free cash flow relative to reported net income Optimal: > 1x	1.03x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	—	0.98x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.02x Fair → Fair Stable Free cash flow relative to reported net income Optimal: > 1x	1.01x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	1.03x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Return on Invested Capital (%)	-16.7% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-13.4% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-20.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-19.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-16.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-12.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-10.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-7.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-6.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	12.9% Good ↑ Good Improving Return earned on debt + equity capital invested Optimal: > 10%	11.5% Good ↑ Good Improving Return earned on debt + equity capital invested Optimal: > 10%	10.8% Good Good Return earned on debt + equity capital invested Optimal: > 10%	10.7% Good Good Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-16.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-13.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-20.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-19.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-18.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-13.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	—	-9.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-7.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	-28.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—
Return on Common Equity (%) (%)	-20.3% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-235%)	-16.3% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-209%)	-29.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-296%)	-24.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-261%)	-19.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-233%)	-14.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-194%)	-8.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-159%)	-8.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-153%)	-7.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-149%)	15.7% Good ↑ Good Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: At sector avg	10.0% Caution ↓ Caution Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-34%)	11.5% Fair Fair Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-24%)	13.2% Fair Fair Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-12%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Interest Coverage (x)	-72.83x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-106.17x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-4840.88x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-2467.22x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-2495.16x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-1520.04x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-1174.85x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-857.31x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-667.23x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-454.83x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-325.64x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-289.17x Weak Weak Operating income divided by interest expense Optimal: > 5x	-260.11x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-32.19M	$-124.09M	$-34.16M	$-53.44M	$-56.87M	$-96.62M	$-104.66M	$-131.62M	$-224.29M	$-34.65M	$-22.97M	$-53.43M	$-39.79M	—

📊 What does each share earn? 5 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Basic EPS, GAAP (USD)	$-0.66	$-0.79	$-0.85	$-0.97	$-1.03	$-0.88	$-0.80	$-0.67	$-1.12	$-26.86	$-23.27	$-20.86	$-12.10	—
Free Cash Flow per Share (USD)	$-0.69	—	$-1.00	$-0.74	$-1.04	—	$-0.64	—	$-1.10	—	$-17.13	$-17.94	$-12.47	—
Book Value per Share (USD)	$3.23	$3.85	$3.47	$4.26	$5.18	$6.17	$7.01	$7.73	$8.37	$-105.11	$-168.22	$-154.87	$-91.84	—
Tangible Book Value per Share (USD)	$3.23	$3.85	$3.47	$4.26	$5.18	$6.17	$7.01	$7.73	$8.37	$-105.11	$-168.22	$-154.87	$-91.84	—
Basic Weighted Avg Shares (shares)	60.43M	—	43.42M	43.23M	43.22M	—	43.16M	43.13M	23.75M	—	664,656	627,589	921,260	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Working Capital (USD)	$212.05M	$246.47M	$141.05M	$174.54M	$214.36M	$256.85M	—	$325.35M	$353.62M	$40.80M	—	—	—	—
Total Equity (USD)	$195.58M	$232.28M	$151.95M	$184.38M	$224.01M	$266.59M	$302.71M	$333.51M	$360.99M	$-131.40M	$-111.81M	$-97.19M	$-84.61M	$-74.00M

📋 What is driving earnings? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Depreciation Expense (USD)	$351.00K	$368.00K	$415.00K	$515.00K	$501.00K	$563.00K	$558.00K	—	$482.00K	$462.00K	$438.00K	$413.00K	$394.00K	—
Net Income, GAAP (USD)	$-39.73M	$-37.80M	$-44.63M	$-44.63M	$-44.63M	$-37.49M	$-26.69M	$-26.69M	$-26.69M	$-20.67M	$-11.14M	$-11.14M	$-11.14M	—
Operating Cash Flow (USD)	$-41.60M	$-33.53M	$-43.32M	$-31.95M	$-44.91M	$-37.06M	$-27.49M	—	$-25.52M	$-18.56M	$-11.13M	$-11.26M	$-11.46M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 4 years · 14 quarters

Kyverna Therapeutics, Inc.

Analytical Summary

14-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare KYTX with peers